Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI)

• J. Capdevila ^[6] ; J. C. Galofré ^[1] ; E. Grande ^[2] ; C. Zafón Llopis ^[6] ; T. Ramón y Cajal Asensio ^[7] ; E. Navarro González ^[3] ; P. Jiménez-Fonseca ^[4] ; J. Santamaría Sandi ^[8] ; J. M. Gómez Sáez ^[9] ; G. Riesco Eizaguirre ^[5]
  1. [1] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  2. [2] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  3. [3] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  4. [4] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  5. [5] Hospital de Móstoles

     Hospital de Móstoles

     Móstoles, España

     
  6. [6] Hospital Universitario Vall d’Hebron, España
  7. [7] Hospital Universitario Santa Creu i Sant Pau, España
  8. [8] Hospital Universitario de Cruces, España
  9. [9] Hospital Universitario de Bellvitge, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 3 (March 2017), 2017, págs. 279-287
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid cancer (DTC) accounts for more than 90 % of all malignancies and its incidence has been rising steadily. For more patients, surgical treatment, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppressive therapy achieve an overall survival (OS) rate of 97.7 % at 5 years. Nevertheless, locoregional recurrence occurs in up to 20 % and distant metastases in approximately 10 % at 10 years. Two-thirds of these patients will never be cured with radioactive iodine therapy and will become RAI-refractory, with a 3-year OS rate of less than 50 %. Over the last decade, substantial progress has been made in the management of RAI-refractory DTC. Given the controversy in some areas, the Spanish Task Force for Thyroid Cancer on behalf of Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and the Spanish Rare Cancer Working Group (GETHI) have created a national joint task force to reach a consensus addressing the most challenging aspects of management in these patients. In this way, multidisciplinary management should be mandatory and nuclear medicine targeted therapy, novel molecular targeted agents, and combinations are currently changing the natural history of RAI-refractory DTC.